Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation

Abstract

Excellent outcomes are reported with rituximab therapy in indolent NHL, both early and late in the disease course. Continued study of this most valuable therapeutic agent is warranted to set the optimal treatment approach leading to cure the majority of patients.